View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medic...

Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has been named the Preferred Sports Medicine Technology Partner of UFC – the world’s premier mixed martial arts organization and one of the foremost global brands in all of sports. Under the terms of the multi-year partnership, Smith+Nephew will activate its brand through UFC’s immense global presence to promote the repair, regeneration and recovery of Sports Medicine injuries through advanced technologies. “...

Baptiste Salaville ... (+4)
  • Baptiste Salaville
  • Bruno Cavalier
  • Gerardo Ibanez
  • Steven Boumans
Oliver Metzger
  • Oliver Metzger

Smith & Nephew : Improvement in the margin only on higher growth and f...

>Improvement in underlying growth is positive, but trading margin still weak - Over recent quarters, Smith & Nephew has shown an improvement in top line momentum, which resulted in strong underlying growth of 7.2% in comparison to only a low single-digit level on average in previous years. This has come in particular on a better performance at Orthopaedics. However, the stronger growth does not convert into a higher profitability. FY 2024 trading margin of 17.5% compa...

 PRESS RELEASE

Smith+Nephew and U.S. Army Institute of Surgical Research to engage in...

Smith+Nephew and U.S. Army Institute of Surgical Research to engage in Master Cooperative Research and Development Agreement Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announced they have entered into a Master Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR). This marks the first time that the USAISR has entered into a master agreement of this nature with an industry-leading medical technology company. The Master CRADA represents an enterprise-wide opportunity for Smith+Nephew across all ...

Oliver Metzger ... (+2)
  • Oliver Metzger
  • Thomas Zlowodzki

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 02/27/2024

The start of the earnings season has halted EPS erosion, which was marked in Europe and more limited in the US. In 2024, EPS should grow twice as fast on the S&P 500 (+10%) vs the Stoxx 600 (+5%). In Europe, the fastest-growing sectors are travel & leisure, banks and industrials. - ...

Oliver Metzger ... (+2)
  • Oliver Metzger
  • Thomas Zlowodzki

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 27/02/2024

L’ouverture de la saison des résultats a mis fin à l’érosion des BPA, qui était forte en Europe et plus limitée aux Etats-Unis. Les BPA devraient ainsi croître en 2024 deux fois plus vite sur le S&P 500 (+10%) que le sur le Stoxx 600 (+5%). En Europe, les secteurs ayant la meilleure dynamique sont le Travel & Leisure, les Banques et l’Industrie. - ...

Oliver Metzger
  • Oliver Metzger

Smith & Nephew : Q4 review – Solid finish to 2023, guidance well refle...

>Q4 review – Solid finish, in line with expectations - Q4 2023 revenues of $ 1,458m (+9.0% y-o-y) were 2% ahead of ODDO BHF/consensus expectations. Underlying growth was 6.4% (vs 6.0%/5.3% expected). Forex tailwind accounted for 40bp. FY trading profit reached $ 970m (+7.7% y-o-y/margin 17.5%), in line with our forecast and consensus. Adjusted EPS of $ 0.83 was +1%/2% vs expectations.Segmental view – Advanced wound management with strongest growth - I...

 PRESS RELEASE

Smith+Nephew announces commercial launch of its AETOS™ Shoulder System...

Smith+Nephew announces commercial launch of its AETOS™ Shoulder System for anatomic and reverse shoulder replacement at AAOS 2024 Annual Meeting Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces full commercial availability of its AETOS Shoulder System in the US, along with 510(k) clearance for its use with ATLASPLAN◊ 3D Planning Software and Patient Specific Instrumentation for total shoulder arthroplasty. Total shoulder arthroplasty is one of the fastest growing segments in Orthopaedics with an estimated 250,000 procedures in the US by 2025.1 Devel...

 PRESS RELEASE

Smith+Nephew to showcase leading, innovative AI-driven robotic-assiste...

Smith+Nephew to showcase leading, innovative AI-driven robotic-assisted solutions for personalized orthopaedic surgery at AAOS 2024 Annual Meeting   Smith+Nephew (LSE: SN, NYSE:SNN), the global medical technology company, announces it will provide a glimpse into the future at AAOS 2024. With a first opportunity to see a forthcoming new feature* for its CORI◊ Surgical System, this exclusive image-agnostic* robotic-assisted surgical solution is designed to further help personalize surgery, advance efficiencies, and optimize performance across Smith+Nephew’s orthopaedic reconstruction portfol...

 PRESS RELEASE

Smith+Nephew unveils expanded Sports Medicine portfolio to enable biol...

Smith+Nephew unveils expanded Sports Medicine portfolio to enable biological healing at AAOS 2024 Annual Meeting 12 February 2024 Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the premiere of its newly acquired CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant alongside the REGENETEN◊ Bioinductive Implant at the AAOS Annual Meeting, demonstrating its leadership with products that enable biological healing for Sports Medicine. Backed by impressive clinical evidence, both technologies are transforming the way healthcare professionals treat soft tissue repair ...

Martin Hall
  • Martin Hall

Hardman & Co Healthcare Index: 2023 – Capital demands dent performance

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (...

 PRESS RELEASE

New study confirms Smith+Nephew’s REGENETEN™ Bioinductive Implant redu...

New study confirms Smith+Nephew’s REGENETEN™ Bioinductive Implant reduces full-thickness rotator cuff re-tear rates¹ by 68% First published randomized controlled trial for market-leading implant demonstrates impressive outcomes for rotator cuff tears                Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces standout results for its REGENETEN Bioinductive Implant from a recently completed randomized controlled trial (RCT). Published , the report concluded that at one-year, medium and large full-thickness rotator cuff tears repai...

Oliver Metzger
  • Oliver Metzger

Smith & Nephew : Q3 review – good momentum, mixed guidance update

>Beat on top line - Q3 2023 revenues of $ 1,357m (+8.6% y-o-y) were 2% ahead of ODDO BHF/consensus. Underlying growth was 7.7% (vs 4.9%/5.0% expected). Forex created a tailwind of 90bp. No bottom line is reported on a quarterly base.Strong development in Sports Medicine & ENT and Orthopaedics - Sports medicine & ENT generated revenues of $ 425m (+11.3% y-o-y), with a strong underlying growth of 11.1%. Sports medicine joint repair showed an underlying ...

Oliver Metzger
  • Oliver Metzger

Smith & Nephew : Strong top line momentum moves up revenue guidance

>Beat on the top line, miss on consensus’ expectations on bottom line - Smith & Nephew’s Q2 revenues of $ 1,379m (+6.7% y-o-y) were 3%/1% compared to ODDO BHF/consensus. The underlying growth in the quarter was 7.8% vs our 5.2% and consensus’ 5.9%. There was no external growth effect, but the forex environment created a headwind of 120bp. H1 trading profit reached $ 417m (margin 15.3%, -5.2% y-o-y), which was in line with our forecast but 6% below consensus. EPS was $...

Smith & Nephew: 1 director

A director at Smith & Nephew maiden bought 9,040 shares at 1,294p and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch